Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antioxidants for lung function?

This article was originally published in The Tan Sheet

Executive Summary

Results of a study "strongly suggest that beta-carotene protects against the decline in forced expiratory volume (FEV) over an eight-year period in the general population, and that beta-carotene and vitamin E are protective in heavy smokers," A. Guenegou, French National Health Institute INSERM, et al., state in the April issue of Thorax. The study followed 535 French subjects age 20-44 over eight years, 40% of whom were non-smokers. FEV was used as an endpoint since oxidative stress is thought to cause airway obstruction and thus lower FEV. An increase of beta-carotene was linked to slower FEV decline, though no association was found for alpha-carotene, vitamin A or vitamin E. Heavy smokers (> 20 cigarettes/day) with low levels of beta-carotene or vitamin E had the steepest FEV decline...

You may also be interested in...

Legal Notebook: Catalyst’s Suit vs. FDA Is Tossed, Avonex Patent Invalidity Verdict Is Reinstated

Court finds US FDA did not impede Catalyst orphan exclusivity for Firdapse as it approved different indication for competing product. Biogen loses 10-year patent battle against competing multiple sclerosis drug makers.

Naturopath Marketing Brain Defense Supplement Anticipates Support For Making TBI Claims

Cover Three Nutritional Brain Defense marketer agrees to pull claims suggesting the supplement beverage can protect against traumatic brain injury after a test the firm on DHA submitted as support contained considerably higher levels of the ingredient than included in the product.

Alnylam Shows Efficacy, Safety With Lumasiran In Vulnerable Pediatric Patients

The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts